Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Malignant Neoplasm
100%
Immune Checkpoint Inhibitor
46%
COVID-19
43%
Cancer
20%
Oncology
19%
Severe Acute Respiratory Syndrome Coronavirus 2
18%
Solid Malignant Neoplasm
18%
Symptomatic Treatment
18%
Pneumonia
16%
Immune-Related Adverse Events
15%
Supportive Care
14%
Lung Cancer
13%
Thrombosis
12%
Diseases
12%
Infection
11%
Immunotherapy
10%
Immunity
10%
Colitis
9%
Hospital Medicine
9%
Cancer Therapy
9%
Overall Survival
9%
Cancer Pain
9%
Hospitalist
9%
Pancreas Adenocarcinoma
9%
Internal Medicine
9%
Adverse Event
9%
Prospective Cohort Study
8%
Cytokine Release Syndrome
8%
Clinician
8%
Venous Thromboembolism
8%
Medicine
8%
Brain Metastasis
8%
Diarrhea
7%
Antibiotics
7%
Cancer Care
7%
Abdominal Cancer
6%
Anticoagulation
6%
Retrospective Study
6%
Cancer Cell
6%
Intensive Care Unit
6%
Reactive Oxygen Species
6%
Outpatient
6%
Infliximab
6%
Lung
5%
Cancer Treatment
5%
Odds Ratio
5%
Patient Advocate
5%
Cohort Analysis
5%
Base
5%
Clinical Significance
5%
Pembrolizumab
5%
Neoplasm
5%
Multivariate Analysis
5%
Toxicity and Intoxication
5%
Meta-Analysis
5%
Keyphrases
Immune Checkpoint Inhibitors
37%
In Cancer
29%
Cancer Patients
27%
COVID-19
22%
Comprehensive Cancer Center
18%
Immune-related Adverse Events
18%
Care Program
12%
Goals of Care
12%
Immune Checkpoint Inhibitor Therapy
12%
Clinical Characteristics
11%
Colitis
10%
Patients with Cancer
10%
Readmission Rates
10%
Solid Tumors
9%
Pancreatic Ductal Adenocarcinoma
9%
Checkpoint Inhibitors
9%
Oncology
9%
Pneumonitis
9%
Propensity Score Analysis
8%
Narrative Review
8%
Unplanned Readmission
8%
Cancer-associated Thrombosis
8%
Invasive Aspergillosis
8%
Brain Metastases
8%
Confidence Interval
7%
Risk Factors
7%
Chemotherapy
7%
Diarrhea
7%
30-day Readmission
7%
Cancer Treatment
6%
Readmission Risk
6%
Retrospective Analysis
6%
Infliximab
6%
Hospitalization
6%
Overall Survival
6%
MD Anderson Cancer Center
5%
Readmission
5%
Medical Oncology
5%
Emergency Department
5%
Cancer Cells
5%
Gastric Cancer
5%
Clinical Significance
5%
Single Institution
5%
Opioids
5%
Corticosteroids
5%
Cancer Therapy
5%
Odds Ratio
5%
Prognostic Value
5%
Mortality Outcomes
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
86%
Immune Checkpoint Inhibitor
21%
Diseases
19%
SARS Coronavirus
15%
Adverse Event
15%
Coronavirinae
15%
Infection
12%
Immunotherapy
10%
Reactive Oxygen Metabolite
10%
Colitis
9%
Cytokine Release Syndrome
8%
Isothiocyanate
8%
Febrile Neutropenia
8%
Invasive Aspergillosis
8%
Pyrrole
8%
Thrombosis
8%
Mould
8%
Abdominal Cancer
8%
FDA Adverse Event Reporting System
8%
Hematologic Malignancy
7%
Chemotherapy
6%
Solid Malignant Neoplasm
6%
Antibiotics
6%
Infliximab
5%
Elimination
5%
Overall Survival
5%